Global Antibody and Recombinant Protein CDMO Market to Cross USD 35 Billion by 2030

Published | 05 November 2024

Global Antibody and Recombinant Protein CDMO Market is flourishing because of a rising demand for biopharma contract development and manufacturing services and increasingly complex processes involved in producing biologics.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global Antibody and Recombinant Protein CDMO Market size at USD 16.70 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global Antibody and Recombinant Protein CDMO Market size to expand at a CAGR of 11.2% reaching a value of USD 35.40 billion by 2030. Major growth factors for Global Antibody and Recombinant Protein CDMO Market include an increasing need for biologics and recombinant protein therapies. Over the forecast period, it is also expected that the growth of Global Antibody and Recombinant Protein CDMO Market will be spurred by the rising incidence of various chronic illnesses, including diabetes and cancer, scientific breakthroughs, and rising investments biopharmaceutical sector.

Sample @ https://www.blueweaveconsulting.com/report/antibody-and-recombinant-protein-cdmo-market/report-sample

Opportunity - Major Acquisitions and Mergers

Many contract development and manufacturing organizations (CDMOs) are entering into mergers and acquisitions to expand their existing capacities. Small companies merge to leverage technology and platforms, while mid-size companies focus on diversifying pipelines through these strategic alliances. For instance, Curia, an American CDMO company, recently acquired Integrity Bio, a formulation and fill-finish company. In another example, Delpharm announced the acquisition of the Meppel pharmaceutical manufacturing facility in the Netherlands from Astellas to strengthen CDMO’s position in the country. Such developments are anticipated to provide lucrative growth opportunities to global antibody and recombinant protein CDMO market during the period in analysis.

Impact of Escalating Geopolitical Tensions on Global Antibody and Recombinant Protein CDMO Market

Intensifying geopolitical tensions among countries spreading across the major regions could bring unprecedented challenges for Global Antibody and Recombinant Protein CDMO Market. A significant effect of geopolitical tensions on market operations is supply chain disruption, which makes it more difficult to get the necessary raw materials and reagents for the manufacturing of antibodies and recombinant proteins. Many exporting nations may apply tariffs or trade restrictions, which might make CDMOs' sourcing techniques more difficult. Product delivery on schedule may be impacted by delays in logistics and transportation caused by conflicts or increased security measures. Increased tensions may result in more stringent regulatory frameworks, which would affect CDMOs' capacity to conduct cross-border operations.

Therapeutics Segment Accounts for Major Market Share  

The therapeutics segment holds the largest share of Global Antibody and Recombinant Protein CDMO Market. The growing prevalence of various chronic diseases owing to changing lifestyles and the rising geriatric populations is fueling the demand for recombinant protein therapeutics for treatment purposes. Recombinant protein therapeutics are widely used to treat various types of cancer. With the increasing prevalence of cancer worldwide, the demand for recombinant proteins is projected to rise only.

North America Holds Leadership Position in Global Market

North America dominates Global Antibody and Recombinant Protein CDMO Market. Expansion of the regional market is aided by the concentration of significant biotechnology and pharmaceutical firms as well as the strong healthcare systems in United States and Canada. However, over the forecast period, the Asia Pacific region is expected to register a significant growth rate. The Asia Pacific Antibody and Recombinant Protein CDMO Market is expected to be driven by the region's growing healthcare spending as well as an increase in research and development initiatives.

Competitive Landscape

Major industry players of Global Antibody and Recombinant Protein CDMO Market include Batavia Biosciences, Grifols, Cerbios-Pharma SA, HALIX, Biovian Oy, Catalent, Goodwin Biotechnology, Cerbios-Pharma SA, Gene Universal Inc., Eurogentec, MabPlex International, and Etinpro (Beijing) Co.

To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Don’t miss the business opportunity in Global Antibody and Recombinant Protein CDMO Market. Consult our analysts to gain crucial insights and facilitate your business growth.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and Global Antibody and Recombinant Protein CDMO Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Antibody and Recombinant Protein CDMO Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Scope of the Report

About Us

BlueWeave Consulting provides comprehensive Market Intelligence (MI) Solutions to businesses regarding various products and services online and offline. We offer all-inclusive market research reports by analyzing qualitative and quantitative data to boost the performance of your business solutions. BlueWeave has built its reputation by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions companies providing agile assistance to make your business endeavors successful.

Contact Us:

BlueWeave Consulting & Research Pvt Ltd

+1 866 658 6826 | +1 425 320 4776 | +44 1865 60 0662

info@blueweaveconsulting.com